# WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

> **NCT03302494** · PHASE3 · TERMINATED · sponsor: **Coherex Medical** · enrollment: 248 (actual)

## Conditions studied

- Stroke

## Interventions

- **DEVICE:** Coherex WaveCrest® Left Atrial Appendage Occlusion System
- **DEVICE:** Watchman® LAA Closure Device

## Key facts

- **NCT ID:** NCT03302494
- **Lead sponsor:** Coherex Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-27
- **Primary completion:** 2023-12-21
- **Final completion:** 2023-12-21
- **Target enrollment:** 248 (ACTUAL)
- **Why stopped:** Study closed due to device design modification
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03302494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03302494, "WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03302494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*